Is pregnancy in MS patients safe and what is its impact on MS course? Real World evidence of 1533 pregnancies in Czech Republic
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023698%3A_____%2F22%3AN0000012" target="_blank" >RIV/00023698:_____/22:N0000012 - isvavai.cz</a>
Alternative codes found
RIV/00843989:_____/22:E0109501 RIV/65269705:_____/22:00076092 RIV/00064173:_____/22:43923038 RIV/00098892:_____/22:10157223 and 11 more
Result on the web
<a href="https://www.sciencedirect.com/science/article/abs/pii/S2211034821006581" target="_blank" >https://www.sciencedirect.com/science/article/abs/pii/S2211034821006581</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.msard.2021.103391" target="_blank" >10.1016/j.msard.2021.103391</a>
Alternative languages
Result language
angličtina
Original language name
Is pregnancy in MS patients safe and what is its impact on MS course? Real World evidence of 1533 pregnancies in Czech Republic
Original language description
Background: A special care of MS women planning a pregnancy is highly demanding especially in the terms of disease modifying treatment (DMD) decisions and counselling regarding periods of conception, pregnancy and postpartum period.Objective: To provide data about impact of pregnancy, delivery or miscarriage/artificial abortion on MS disease course in Czech women with MS based on analysis of retrospective data from the Czech national registry ReMuS.Methods: The analysis focused on women with MS with at least one record of pregnancy in the registry. Clinical data (EDSS, relapses) were collected prior to conception, during pregnancy and after delivery or miscarriage/ artificial abortion. These data were analysed according to baseline characteristics of DMD treatment prior to conception and according to breastfeeding status.Results: A total of 1 533 pregnancies were analysed from the period of 2013 until 31st December 2019. The occurrence of relapses and worse EDSS was significantly related to the treatment with escalation therapy prior to conception. Relapses were significantly more frequent in women who breastfed less than 3 months than in women who breastfed more than 3 months or did not breastfeed at all. Patients treated with either fingolimod or natalizumab prior to pregnancy were significantly more likely to develop relapses during pregnancy.Conclusion: Pregnancy and postpartum period were generally safe for Czech women with MS. Better disease outcomes were observed in those who had been treated with first line injectable DMDs prior to conception and those who either breastfed more than 3 months or did not breastfeed at all. We confirmed the assumption of rebound phenomenon of MS after discontinuation of treatment due to planned pregnancy both for fingolimod and natalizumab.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30210 - Clinical neurology
Result continuities
Project
—
Continuities
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Others
Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
MULTIPLE SCLEROSIS AND RELATED DISORDERS
ISSN
2211-0348
e-ISSN
2211-0356
Volume of the periodical
59
Issue of the periodical within the volume
MAR 2022
Country of publishing house
GB - UNITED KINGDOM
Number of pages
7
Pages from-to
103391
UT code for WoS article
000791995000014
EID of the result in the Scopus database
2-s2.0-85125324831